RecruitingNot ApplicableNCT04935619

Extended Effects of Cannabis Abstinence on Clinical Symptoms and Cognition in Depression

Effects of Extended Cannabis Abstinence on Clinical and Cognitive Outcomes in Patients With Co-Morbid Major Depressive and Cannabis Use Disorders


Sponsor

Centre for Addiction and Mental Health

Enrollment

52 participants

Start Date

Jul 21, 2021

Study Type

INTERVENTIONAL

Conditions

Summary

The prevalence of major depressive disorder (MDD) is \~5.0%, and rates of co-occurring SUDs in these patients approach 40-50%. Specifically, rates of co-morbid cannabis use disorder (CUD) in patients with MDD are elevated 2-3 fold compared to 2.9% in the general population, and is associated with poorer treatment outcomes and impaired cognitive and psychosocial functioning in comparison to MDD patients without CUD. Most studies of cannabis use in MDD are cross-sectional in design, and therefore causal relationships are unclear. This study investigates the effects of cannabis abstinence over a 28-day period in patients with MDD with co-occurring CUD using a randomized controlled design, namely contingent reinforcement.


Eligibility

Min Age: 18 YearsMax Age: 55 Years

Plain Language Summary

Simplified for easier understanding

This study examines how stopping cannabis (marijuana) use over an extended period affects mood, thinking, and depression symptoms in adults who both use cannabis heavily and have major depression. **You may be eligible if...** - You are between 18 and 55 years old - You have been diagnosed with cannabis use disorder (moderate or severe) - You have also been diagnosed with major depressive disorder (clinical depression) - You are currently on a stable dose of antidepressant medication for at least 3 months - Your depression symptoms are in the moderate range (HDRS-17 score 12-25) - You are not currently seeking treatment to quit cannabis **You may NOT be eligible if...** - You have a substance use disorder involving alcohol or other drugs (not cannabis) - You have a history of psychosis or other major psychiatric conditions - You are pregnant - You have a significant neurological condition Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BEHAVIORALContingency Reinforcement

Subjects will be randomly assigned on a 1:1 ratio to either the Contingency Reinforcement or Non-Contingency Reinforcement Intervention prior to their in-person screening visit.

BEHAVIORALNon-Contingency Reinforcement

Subjects will be randomly assigned on a 1:1 ratio to either the Contingency Reinforcement or Non-Contingency Reinforcement Intervention prior to their in-person screening visit.


Locations(1)

Centre for Addiction and Mental Health

Toronto, Ontario, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04935619


Related Trials